Acute myeloid leukemia blast cell (AML blast)

Acute myeloid leukemia (AML) blast cells are immature, malignant myeloid precursors that fail to differentiate into mature blood cells, instead proliferating uncontrollably within the bone marrow and peripheral blood [StatPearls, 2023]. These cells are the defining feature of AML and are characterized by a variety of genetic mutations and surface markers that drive their survival and resistance to apoptosis [NCI, 2024]. While AML blast cells represent a cellular population rather than a single molecular target, they are the primary focus of therapeutic intervention in leukemia [American Cancer Society, 2024]. Treatment strategies range from non-specific cytotoxic chemotherapies, such as cytarabine and anthracyclines, to highly specific targeted agents that inhibit key drivers like FLT3, IDH1/2, or BCL-2 [PubMed: 30321413]. The presence of leukemic stem cells within the blast population often contributes to disease relapse and remains a significant challenge in achieving long-term remission [Nature, 2019]. Monitoring these cells via flow cytometry and molecular testing is essential for diagnosis, prognosis, and assessing minimal residual disease [StatPearls, 2023]. Surface antigens such as CD33 and CD123 are frequently expressed on these blasts, serving as targets for antibody-drug conjugates and immunotherapy [American Cancer Society, 2024]. Ultimately, the eradication of the AML blast population is the central goal of induction and consolidation therapy to restore normal hematopoiesis [NCI, 2024].

Other names

MyeloblastLeukemic blastAML blastMalignant myeloblast

Therapeutic agents target AML blast cells through diverse mechanisms, including the induction of DNA damage, inhibition of anti-apoptotic proteins like BCL-2, blockade of oncogenic tyrosine kinases such as FLT3, and antibody-mediated delivery of cytotoxic conjugates to surface antigens like CD33 [American Cancer Society, 2024; PubMed: 30321413].